Prolongation of Epidural Analgesia Using Solid Lipid Nanoparticles as Drug Carrier for Lidocaine

2012 ◽  
Vol 37 (2) ◽  
pp. 159-165 ◽  
Author(s):  
Fujian Leng ◽  
Jiangling Wan ◽  
Wei Liu ◽  
Bo Tao ◽  
Xuehong Chen
Keyword(s):  
Epidural Analgesia ◽  
Solid Lipid Nanoparticles ◽  
Drug Carrier ◽  
Lipid Nanoparticles ◽  
Solid Lipid

Effect of Surfactant on Characteristics of Solid Lipid Nanoparticles (SLN)

2011 ◽  
Vol 364 ◽  
pp. 313-316 ◽  
Author(s):  
Karn Orachai Kullavadee ◽  
Ruktanonchai Uracha ◽  
Siwaporn Meejoo Smith
Keyword(s):  
Particle Size ◽  
Solid Lipid Nanoparticles ◽  
Drug Carrier ◽  
Tween 80 ◽  
Lipid Nanoparticles ◽  
Great Promise ◽  
Solid Lipid ◽  
Alternative Drug ◽  
Model Drug ◽  
Drug Free

SLN have shown a great promise as an alternative drug carrier for intravenous and dermal applications. This work focuses on the basic properties of drug-free Compritol® ATO 888 based SLN systems by using cationic surfactant (CPC) and nonionic surfactant (Tween 80). Effects of surfactant on the physical properties of SLNs were investigated in the absence of model drug to avoid the interaction between drug and surfactant. These SLN samples have different particle size, zeta potential and morphology. DSC was used to quantify the crystallinity of SLN systems. It was found that %RI of both SLNs was similar, indicating that types of surfactant did not affect on crystallization of solid lipid. Spherical-like particle was observed with SLN-C, while rod-like particle was found with SLN-T. The results demonstrated that surfactant plays an important role on SLN physical characteristics.

scholarly journals Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1183
Author(s):  
Mantosh Kumar Satapathy ◽  
Ting-Lin Yen ◽  
Jing-Shiun Jan ◽  
Ruei-Dun Tang ◽  
Jia-Yi Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticles ◽  
Drug Carrier ◽  
Lipid Nanoparticles ◽  
Therapeutic Drug ◽  
Target Specificity ◽  
Carrier System ◽  
Nanodrug Delivery ◽  
Solid Lipid ◽  
The Brain

The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.

Novel Approaches of Solid Lipid Nanoparticles as Drug Carrier

2021 ◽  
pp. 107-143
Author(s):  
Heba A. Gad ◽  
Reham S. Elezaby ◽  
Mai Mansour ◽  
Rania M. Hathout
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Drug Carrier ◽  
Lipid Nanoparticles ◽  
Solid Lipid ◽  
Novel Approaches

scholarly journals DESIGN, DEVELOPMENT AND CHARACTERIZATION OF PACLITAXEL LOADED SOLID LIPID NANOPARTICLES AS A COLLOIDAL DRUG CARRIER

2019 ◽  
pp. 333-340
Author(s):  
INDRAYANI D. RAUT ◽  
AREHALLI S. MANJAPPA ◽  
SHRINIVAS K. MOHITE ◽  
RAJENDRA C. DOIJAD
Keyword(s):  
Particle Size ◽  
Sustained Release ◽  
Stearic Acid ◽  
Solid Lipid Nanoparticles ◽  
Drug Carrier ◽  
Drug Loading ◽  
Spherical Shape ◽  
Lipid Nanoparticles ◽  
Solid Lipid ◽  
Soya Lecithin

Objective: This study was aimed to design and characterize Paclitaxel-loaded Solid Lipid Nanoparticles (SLNs) to achieve site specificity,reduce toxicity and sustained release pattern. Methods: Paclitaxel-loaded solid lipid nanoparticles were fabricated by microemulsion followed by probe sonication technique using stearic acid as lipid and stabilized of the mixture of surfactants. In this study, 32 full factorial design was employed for optimizing the concentration of lipid as stearic acid and surfactant (soya lecithin) for the nanoparticles. The optimization was done by studying the dependent variable of particle size and % entrapment efficiency. Results: The results showed that the paclitaxel-loaded solid lipid nanoparticles prepared with the concentration of 33.31 % stearic acid and 500 mg of soya lecithin were optimum characteristic than other formulations. They showed the average particles size 149±4.10 nm and PDI 250±2.04. The zeta potential, % EE and % drug loading capacity was found to be respectively-29.7, 93.38±1.90 and 0.81±0.01. The optimized batch of Paclitaxel SLNs exhibited spherical shape with smooth surface analyzed by Transmission Electron Microscopy. In vitro study showed sustained release profile and was found to follow Higuchi Kinetics Equation. Conclusion: The SLNs of paclitaxel m et al. l the requirements of a colloidal drug delivery system. They had a particle size in nanosize; their size distribution was narrow and all the particles were in a spherical shape.

scholarly journals SOLID LIPID NANOPARTICLES (SLNs) AS NANO DRUG DELIVERY CARRIERS: PREPARATION, CHARACTERIZATION AND APPLICATION

2019 ◽  
pp. 1-9
Author(s):  
MONA QUSHAWY ◽  
ALI NASR
Keyword(s):  
Drug Delivery ◽  
Solid Lipid Nanoparticles ◽  
Colloidal Particles ◽  
Drug Carrier ◽  
Physical Stability ◽  
Controlled Drug Release ◽  
Drug Carriers ◽  
Colloidal Dispersion ◽  
Lipid Nanoparticles ◽  
Solid Lipid

Over the last few years, there has been a significant consideration of solid lipid nanoparticles (SLNs) as an alternative method to other colloidal dispersion methods for drug delivery. Special consideration has been given to the use of SLNs as a drug carrier in recent years. SLNs are aqueous dispersions in which the colloidal particles consist of solid lipids that are biodegradable. As a result of their physical stability, the protection of the entrapped drug from decomposition, the provision of controlled drug release, and the exceptional acceptability, SLNs have several advantages over other drug carriers. This article focuses on the techniques of SLNs preparation and characterization, the effect of formulation variables on SLNs properties, the routes of administration, and the pharmaceutical applications. The data used for this review was collected by searching on Google Scholar and PubMed using the following keywords during the period from 2010 to date.

scholarly journals Acyclovir-Loaded Solid Lipid Nanoparticles: Optimization, Characterization and Evaluation of Its Pharmacokinetic Profile

Nanomaterials ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 1785
Author(s):  
Haniza Hassan ◽  
Ramatu Omenesa Bello ◽  
Siti Khadijah Adam ◽  
Ekram Alias ◽  
Meor Mohd Redzuan Meor Mohd Affandi ◽  
...  
Keyword(s):  
Solid Lipid Nanoparticles ◽  
Oral Bioavailability ◽  
Alternative Pathway ◽  
Drug Carrier ◽  
Antiviral Drug ◽  
Lipid Nanoparticles ◽  
Pharmacokinetic Parameters ◽  
Therapeutic Concept ◽  
Solid Lipid ◽  
Acyclovir Treatment

Acyclovir is an antiviral drug used for the treatment of herpes simplex virus infection. Its oral bioavailability is low; therefore, frequent and high doses are prescribed for optimum therapeutic efficacy. Moreover, the current therapeutic regimen of acyclovir is associated with unwarranted adverse effects, hence prompting the need for a suitable drug carrier to overcome these limitations. This study aimed to develop solid lipid nanoparticles (SLNs) as acyclovir carriers and evaluate their in vivo pharmacokinetic parameters to prove the study hypothesis. During the SLN development process, response surface methodology was exploited to optimize the composition of solid lipid and surfactant. Optimum combination of Biogapress Vegetal 297 ATO and Tween 80 was found essential to produce SLNs of 134 nm. The oral bioavailability study showed that acyclovir-loaded SLNs possessed superior oral bioavailability when compared with the commercial acyclovir suspension. The plasma concentration of acyclovir-loaded SLNs was four-fold higher than the commercial suspension. Thus, this investigation presented promising results that the method developed for encapsulation of acyclovir offers potential as an alternative pathway to enhance the drug’s bioavailability. In conclusion, this study exhibited the feasibility of SLNs as an oral delivery vehicle for acyclovir and therefore represents a new promising therapeutic concept of acyclovir treatment via a nanoparticulate drug delivery system.

Sign in / Sign up

Export Citation Format

Share Document